Skin cancers in elderly patients

Anti-Cancer Agents in Medicinal Chemistry

Volumn 13, Issue 9, 2013, Pages 1406-1411

  Malaguarnera, Giulia ^a   Giordano, Maria ^b   Cappellani, Alessandro ^b   Berretta, Massimiliano ^c   Malaguarnera, Michele ^a   Perrotta, Rosario Emanuele ^b  

^a UNIVERSITY OF CATANIA   (Italy)

^b UNIVERSITY OF CATANIA   (Italy)

^c CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

Basocellular carcinoma; Diagnosis; Elderly; Immunosenescence; Melanoma; Skin cancers; Squamocellular carcinoma; Treatment

Indexed keywords

ANTINEOPLASTIC AGENT; PROSTAGLANDIN SYNTHASE INHIBITOR; RETINOID;

AGED; AGING; ARTICLE; BASAL CELL CARCINOMA; CANCER GROWTH; CARCINOGENESIS; CELL FUNCTION; CELL PROLIFERATION; FAMILY HISTORY; HUMAN; IMMUNE RESPONSE; IMMUNOPATHOLOGY; MORBIDITY; RISK FACTOR; SKIN CANCER; SKIN COLOR; SUN EXPOSURE; SURVIVAL RATE; T LYMPHOCYTE; IMMUNOLOGY; SKIN NEOPLASMS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; HUMANS; SKIN NEOPLASMS;

EID: 84888265911     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/18715206113136660349     Document Type: Article

References (113)

1. Dolianitis, C.; Kelly, J.; Wolfe, R.; Simpson, P. Comparative performance of 4 dermoscopic algorithms by nonexperts for the diagnosis of melanocytic lesions. Arch. Dermatol., 2005, 141, 1008-1014.
2. Guerry IV, Synnestvedt, M.; Elder, D.E.; Schultz, D. Lessons from tumor progression: the invasive radial growth phase of melanoma is common, incapable of metastasis, and indolent. J. Investig. Dermatol., 1993, 100, 342S-345S.
3. Johnson, T.M.; Smith II, Nelson, B.R.; Chang, A. Current therapy for cutaneous melanoma. J. Am. Acad. Dermatol., 1995, 32, 689-707.
4. Green, M.S. The changing controversy over surgical resection margins for stage I cutaneous melanoma. Mount Sinai J. Med., 1991, 58, 341-346.
5. O'Rourke, M.G.E.; Altmann, C.R. Melanoma recurrence after excision: Is a wide margin justified? Ann. Surg., 1993, 217, 2-5.
6. Balch, C.M.; Urist, M.M.; Karakousis, C.P. Efficacy of 2-cm surgical margins for intermediate-thickness melanomas (1 to 4 mm): results of a multi-institutional randomized surgical trial. Ann. Surg., 1993, 218, 262-269
7. Ringborg, U.; Andersson, R.; Eldh, J. Resection margins of 2 versus 5 cm for cutaneous malignant melanoma with a tumor thickness of 0.8 to 2.0 mm: A randomized study by the Swedish Melanoma Study Group. Cancer. 1996, 77, 1809-1814
8. Bowen, J.T. Precancerous dermatoses. J. Cutan. Dis., 1912, 30, 241-55.
9. Cox, N.H.; Eedy, D.J.; Morton, C.A. Guidelines for management of bowen's disease. british association of dermatologists. Br. J. Dermatol., 1999, 141, 633-41.
10. Nguyen, T.H.; Yoon, J.Y. Squamous cell carcinoma. In: Rigel DS, Friedman RJ, Dzubow LM, Reintgen DS, Bystryn JC, Marks R, editors. Cancer of the Skin. Philadelphia: Elsevier Saunders, 2005:133-50.
11. Stern, R.S.; Weinstein, M.C.; Baker, S.G. Risk reduction for nonmelanoma skin cancer with childhood sunscreen use. Arch. Dermatol., 1986, 122, 537-45.
12. Kelfkens, G.; de Gruijl, F.R.; van der Leun, J.C. Ozone depletion and increase in annual carcinogenic ultraviolet dose. Photochem. Photobiol., 1990, 52, 819-23.
13. Balducci, L.; Beghe, C. Cancer and age in the USA. Crit. Rev. Oncol/Hematol., 2001, 37, 137-145
14. Lens, M.B.; Dawes, M. Global perspectives of contemporary epidemiological trends of cutaneous malignant melanoma. Br. J. Dermatol., 2004, 150, 179-185.
15. American Cancer Society. Cancer Facts and Figures 2009. Atlanta, GA: American Cancer Society; 2009.
16. Jemal, A.; Devesa, S.S.; Hartge, P.; Tucker, M.A. Recent trends in cutaneous melanoma incidence among whites in the United States. J. Natl. Cancer Inst., 2001, 93, 678-683.
17. Howe, H.L.; Wingo, P.A.; Thun, M.J. et al. Annual report to the nation on the status of cancer (1973 through 1998), featuring cancers with recent increasing trends. J. Natl. Cancer Inst., 2001, 93, 824-842.
18. Van Durme, D.J.; Ferrante J.M.; Pal, N et al. Demographic predictors of melanoma stage at diagnosis. Arch. Family Med., 2000, 9, 606-611.
19. ACS (2005) Cancer Facts and Figures 2005. Atlanta: American Cancer Society
20. Rogers, H.W.; Martin, A. Incidence Estimate of Nonmelanoma Skin Cancer in the United States, 2006. Arch. Dermatol., 2010, 146, 283-287.
21. Jemal, A.; Siegel, R.; Ward, E.; Hao, Y.; XU, J.; Thun, J. M. Cancer statistics, 2009. CA Cancer J. Clin., 2009, 59, 225-249.
22. Blackwood, M.A.; Holmes, R.; Synnestvedt, M.; Young, M.; George, C.; Yang, H. et al. Multiple primary melanoma revisited. Cancer, 2002, 94(8), 2248-55.
23. Kroumpouzos, G.; Konstadoulakis, M.M.; Cabral, H.; Karakousis, C.P. Risk of basal cell and squamous cell carcinoma in persons with prior cutaneous melanoma. Dermatol. Surg., 2000, 26(6), 547-50.
24. Marghoob, A.A.; Slade, J.; Salopek, T.G.; Kopf, A.W.; Bart, R.S.; Rigel, D.S. Basal cell and squamous cell carcinomas are important risk factors for cutaneous malignant melanoma. Screening implications. Cancer, 1995, 75(2 Suppl), 707-14.
25. Ridley, A.J.; Whiteside, J.R.; Mc Millan, T.J.; Allinson, S.L. Cellular and sub-cellular responses to UVA in relation to carcinogenesis. Int. J. Radiat. Biol., 2009, 85, 177-95
26. Runger, T.M. How different wavelengths of the ultraviolet spectrum contribute to skin carcinogenesis: The role of cellular damage responses. J. Invest. Dermatol., 2007, 127, 2103-05
27. Weinstock, M.A. Assessment of sun sensitivity by questionnaire: Validity of items and formulation of a prediction rule. J. Clin. Epidemiol., 1992, 45(5), 547-52.
28. Uter, W.; Pfahlberg, A.; Kalina, B.; Kolmel, K.F.; Gefeller, O. Inter-relation between variables determining constitutional UV sensitivity in Caucasian children. Photodermatol. Photoimmunol. Photomed., 2004, 20(1), 9-13.
29. Valverde, P.; Healy, E.; Jackson, I.; Rees, J.L.; Thody, A.J. Variants of the melanocyte-stimulating hormone receptor gene are associated with red hair and fair skin in humans [see comment]. Nat. Genet., 1995, 11(3), 328-30.
30. Zanetti, R.; Prota, G.; Napolitano, A.; Martinez, C.; Sancho-Garnier, H.; Osterlind, A. et al. Development of an integrated method of skin phenotype measurement using the melanins. Melanoma Res., 2001, 11(6), 551-7.
31. Xu, L.Y.; Koo, J. Predictive value of phenotypic variables for skin cancer: Risk assessment beyond skin typing. Int. J. Dermatol., 2006, 45(11), 1275-83
32. Cockburn, M.; Hamilton, A.; Mack, T. The simultaneous assessment of constitutional, behavioral, and environmental factors in the development of large nevi. Cancer Epidemiol. Biomarkers Prev., 2007, 16(2), 200-6.
33. Levine, J.; Kopf, A.W.; Rigel, D.S.; Bart, R.S.; Hennessey, P.; Friedman, R.J. et al. Correlation of thicknesses of superficial spreading malignant melanomas and ages of patients. J. Dermatol. Surg. Oncol., 1981, 7, 311-316.
34. Tsao, H.; Bevona, C.; Goggins, W.; Quinn, T. The transformation rate of moles (melanocytic nevi) into cutaneous melanoma: A population-based estimate. Arch. Dermatol., 2003, 139, 282-288
35. Lange, J.R.; Balch, C.M. Melanoma in older patients. American Society of Clinical Oncology: ASCO Educational Book 2008.
36. Sunderkotter, C.; Kalden, H.; Luger, T.A. Aging and the skin immune system. Arch. Dermatol., 1997, 133, 1256-1263.
37. Marks, R. Epidemiology of melanoma. Clin. Exp. Dermatol., 2000, 25, 459-463.
38. Cox, C.E.; Dupont, E.; Whitehead, G.F.; Ebert, M.D.; Nguyen, K.; Peltz, E.S. et al. Age and body mass index may increase the chance of failure in sentinel lymph node biopsy for women with breast cancer. Breast J., 2002, 8, 88-91.
39. Testori, A.; Stanganelli, I.; Della Grazia, L.; Mahadavan, L. Diagnosis of Melanoma in the elderly and surgical implications. Surg. Oncol., 2004, 13, 211-221.
40. Ho, W.L.; Murphy, G.M. Update on the pathogenesis of posttransplant skin cancer in renal transplant recipients. Br. J. Dermatol., 2008, 158, 217-24
41. Fritschi, L.; Siemiatycki, J. Melanoma and occupation: Results of a case-control study. Occup. Environ. Med., 1996, 53(3), 168-73.
42. Armstrong, B.K.; Kricker, A. The epidemiology of UV induced skin cancer. J. Photochem. Photobiol., 2001, 63, 8-18.
43. Strickland, P.T.; Vitasa, B.C.; West, S.K.; Rosenthal, F.S.; Emmett, E.A.; Taylor, H.R. Qualitative carcinogenesis in man: Solar ultraviolet B dose dependence of skin cancer in Maryland watermen. J. Natl. Cancer Inst., 1989, 81, 1910-1913.
44. Ramirez, C.C.; Federman, D.G.; Kirsner, R.S. Skin cancer as an occupational disease: The effect of ultraviolet and other forms of radiation. Int. J. Dermatol., 2004, 44, 95-100
45. Nole, G.; Johnson, A.W. An analysis of cumulative lifetime solar ultraviolet radiation exposure and the benefits of daily sun protection. Dermatol. Ther., 2004, 17, 57-62
46. Darlington, S.; Williams, G.; Neale, R.; Frost, C.; Green, A. A randomized controlled trial to assess sunscreen application and beta carotene supplementation in the prevention of solar keratoses. Arch. Dermatol., 2003, 139, 451-455.
47. Naylor, M.F.; Boyd, A.; Smith, D.W.; Cameron, G.S.; Hubbard, D.; Nelder, K.H. High sun protection factor sunscreens in the suppression of actinic neoplasia. Arch. Dermatol., 1995, 131, 170-175.
48. Pandeya, N.; Purdie, D.M.; Green, A.; Williams, G. Repeated occurrence of basal cell carcinoma of the skin and multifailure survival analysis: Follow-up data from the Nambour Skin Cancer Prevention Trial. Am. J. Epidemiol., 2005, 161, 748-754
49. Vågerö, D.; Swerdlow, A.J.; Beral, V. Occupation and malignant melanoma: A study based on cancer registration data in England and Wales and in Sweden. Br. J. Ind. Med., 1990, 47(5), 317-24.
50. Bruzell, E.M.; Johnsen, B.; Aalerud, T.N.; Christensen, T. Evaluation of eye protection filters for use with dental curing and bleaching lamps. J. Occup. Environ. Hyg., 2007, 4(6), 432-9.
51. Malaguarnera, M.; Laurino, A.; Di Mauro, S.; Motta, M.; Di Fazio, I.; Maugeri, D. The comorbidities of elderly oncologic patients. Arch. Gerontol. Geriatr., 2000, 30, 237-44.22
52. Finkel, T.; Serrano, M.; Blasco, M.A. The common biology of cancer and ageing. Nature, 2007, 448, 767-74.
53. Hanahan, D.; Weinberg, R.A. The hallmarks of cancer. Cell, 2000, 100(1), 57-70.
54. Anisimov, V.N. Cancer and aging. Arch. Geschwultsforsch., 1985, 55, 421-428.
55. Ginaldi, L.; De Martinis, M.; D'Ostilio, A.; Marini, L.; Loreto, M.F.; Corsi, M.P.; Quaglino, D. The immune system in the elderly: I. Specific humoral immunity. Immunol. Res., 1999a, 20, 101-108.
56. Ginaldi, L.; De Martinis, M.; D'Ostilio, A.; Marini, L.; Loreto, M.F.; Martorelli, V.; Quaglino, D. The immune system in the elderly: II. Specific cellular immunity. Immunol. Res., 1999b, 20, 109-115.
57. Klein, E.; Holtermann, O.A.; Papermaster, B.; Milgrom, H.; Rosner, D.; Klein, L.; Walker, M.J.; Zbar, B. Immunologic approaches to various types of cancer with the use of BCG and purified protein derivatives. Natl. Cancer Inst. Monogr., 1973, 39, 229-242.
58. Lynch, S.A.; Houghton, A.N. Cancer immunology. Curr. Opin. Oncol., 1993, 5(1), 145-50.
59. Malaguarnera, L.; Ferlito, L.; Di Mauro, S.; Imbesi, R.M.; Scalia, G.; Malaguarnera, M. Immunosenescence and cancer: A review. Arch. Gerontol. Geriatr., 2001, 32(2), 77-93
60. Malaguarnera, L.; Ferlito, L.; Imbesi, R.M.; Gulizia, G.S.; Di Mauro, S.; Maugeri, D.; Malaguarnera, M.; Messina, A. Immunosenescence: A review. Arch. Gerontol. Geriatr., 2001, 32, 1-14.
61. Storkus, W.J.; Dawson, J.R. Target structures involved in natural killing (NK): Characteristics, distribution, and candidate molecules. Crit. Rev. Immunol., 1991, 10(5), 393-416.
62. Mariani, E.; Monaco, M.C.; Cattini, L.; Sinoppi, M.; Facchini, A. Distribution and lytic activity of NK cell subsets in the elderly. Mech. Ageing Dev., 1994, 76(2-3), 177-87.
63. Kutza, J.; Murasko, D.M. Age-associated decline in IL-2 and IL-12 induction of LAK cell activity of human PBMC samples. Mech. Ageing Dev., 1996, 90(3), 209-22.
64. Krishnaraj, R.; Svanborg, A. Preferential accumulation of mature NK cells during human immunosenescence. J. Cell Biochem., 1992, 50(4), 386-91.
65. Effros, R.B. Long-term immunological memory against viruses. Mech. Ageing Dev., 2000, 121, 161-71.
66. Gruver, A.L.; Hudson, L.L.; Sempowski, G.D. Immunosenescence of ageing. J. Pathol., 2007, 211, 144-56.
67. Malaguarnera, L.; Cristaldi, E.; Malaguarnera, M. The role of immunity in elderly cancer. Crit. Rev. Oncol. Hematol., 2010 74, 40-60
68. Sexton, M.; Jones, D.B.; Maloney, M.E. Histologic pattern analysis of basal cell carcinoma. Study of a series of 1039 consecutive neoplasms. J. Am. Acad. Dermatol., 1990, 23, 1118-26
69. Rippey, J.J. Why classify basal cell carcinomas? Histopathology, 1998, 32, 393-98
70. Beham, A.; Regauer, S.; Soyer, H.P.; Beham-Schmid, C. Keratoacanthoma: A clinically distinct variant of well differentiated squamous cell carcinoma. Adv. Anat. Pathol., 1998, 5, 269
71. Chang, C.K.; Jacobs, I.A.; Vizgirda, V.M.; Salti, G.I. Melanoma in the elderly patient. Arch. Surg., 2003, 138, 1135-1138.
72. MacKie, R.M. Malignant melanoma: Clinical variants and prognostic indicators. Clin. Exp. Dermatol., 2000, 25, 471-475.
73. Azzola, M.F.; Shaw, H.M.; Thompson, J.F.; Seng-jaw, S.; Scolyer, R.A.; Watson, G.F. et al. Tumor mitotic rate is a more powerful prognostic indicator than ulceration in patients with primary cutaneous melanoma: An analysis of 3661 patients from a single center. Cancer, 2003, 97, 1488-1498.
74. Francken, A.B.; Shaw, H.M.; Thompson, J.F.; Seng-jaw, S.; Accortt, N.A.; Azzola, M.F. et al. The prognostic importance of tumor mitotic rate confirmed in 1317 patients with primary cutaneous melanoma and long follow-up. Ann. Surg. Oncol., 2004, 11, 426-433.
75. Gimotty, P.A.; Elder, D.E.; Fraker, D.L.; Jeffrey, B.; Kimberly, S.; Rosalie, E. et al. Identification of high-risk patients among those diagnosed with thin cutaneous melanomas. J. Clin. Oncol., 2007, 25, 1129-1134.
76. Sassen, S.; Shaw, H.M.; Colman, M.H.; Scolyer, R.A.; Thompson, J.F. The complex relationships between sentinel node positivity, patient age, and primary tumor desmoplasia: Analysis of 2303 melanoma patients treated at a single center. Ann. Surg. Oncol., 2008, 15, 630-637.
77. Alexander, H.R.; Turnbull, A.D.; Salamone, J.; Keefe, D.; Melendez, J. Upper abdominal cancer surgery in the very elderly. J. Surg. Oncol., 1991, 47, 82-86.
78. MacKie, R.M.; Hole, D.; Hunter, J.A. et al. Cutaneous malignant melanoma in Scotland: Incidence, survival, and mortality, 1979-94. The Scottish Melanoma Group. BMJ., 1997, 315, 1117-1121.
79. Ramesh, H.S.; Pope, D.; Gennari, R.; Audisio, R.A. Optimising sur-gical management of elderly cancer patients. World J. Surg. Oncol., 2005, 3, 17
80. Balch, C.M.; Soong, S.J.; Gershenwald, J.E. et al. Prognostic factors analysis of 17,600 melanoma patients: Validation of the Ameri-can Joint Committee on Cancer melanoma staging system. J. Clin. Oncol., 2001, 19, 3622-3634.
81. Jemal, A.; Siegel, R.; Ward, E. et al. Cancer statistics, 2008. CA Cancer J. Clin., 2008, 58, 71-96.
82. Sondak, V.K.; Taylor, J.M.; Sabel, M.S. et al. Mitotic rate and younger age are predictors of sentinel lymph node positivity: Lessons learned from the generation of a probabilistic model. Ann. Surg. Oncol., 2004, 11, 247-258.
83. Roulin, D.; Matter, M.; Bady, P.; Lienard, D.; Gugerli, O.; Boubaker, A. et al. Prognostic value of sentinel node biopsy in 327 prospective melanoma patients from a single instituition. Eur. J. Surg. Oncol., 2008, 34, 673-9.
84. Wainstein, A.J.A.; Belfort, F.A. Conduta para o melanoma cutaneo. Rev. Col. Bras. Cir., 2004, 31, 204-14.
85. Morton, D.L.; Wen, D.R.; Cochran, A.J. Management of early stage melanoma by intraoperative lymphatic mapping and selective lymphadenectomy an alternative to routine lymphoadenectomy or watch and wait. Surg. Oncol. Clin. North Am., 1992, 1, 247-259.
86. Oliveira, A.F.; Santos, I.D.A.O.; Tucunduva, T.C.M.; Sanches, L.G.; Oliveira Filho, R.S.; Enokihara, M.M.S.S. et al. Sentinel lymph node biopsy in cutaneous melanoma. Acta. Cir. Bras., 2007, 22, 332-6.
87. Euvrard, S.; Kanitakis, J.; Claudy, A. Skin cancers after organ transplantation. N. Engl. J. Med., 2003, 348, 1681-91.
88. Bialy, T.L.; Whalen, J.; Veledar, E.; Lafreniere, D.; Spiro, J.; Chartier, T.; Chen, S.C. Mohs micrographic surgery vs traditional surgical excision: A cost comparison analysis. Arch Dermatol., 2004, 140, 736-42
89. Bernstein, P.E. Mohs '98: Single-procedure Mohs surgery with immediate reconstruction. Otolaryngol. Head Neck Surg., 1999, 120, 184-9.
90. Barlow, J.O.; Zalla, M.J.; Kyle, A.; DiCaudao, D.J.; Lim, K.K.;Yiannias, J.A. Treatment of basal cell carcinoma with curettage alone. J. Am. Acad. Dermatol., 2006, 54, 1034-1039.
91. Swanson, N.A. Mohs surgery: Technique, indications, applications, and the future. Arch Dermatol., 1983, 119, 761-773.
92. Drake, L.A.; Dinehart, S.M.; Goltz, R.W.; Graham, G.F.; Hordinsky, M.K.; Lewis, C.W.; Pariser, D.M.; Salasche, S.J.; Skouge, J.W.; Chanco Turner, M.L.; Webster, S.B.; Whitaker, D.C.; Butler, B.; Lowery, B.J. Guidelines of care for Mohs micrographic surgery. J. Am. Acad. Dermatol., 1995, 33(2), 271-278.
93. Veronesi, U.; Testori, A. Melanoma. Diagnosis and specialist treatment. Milan: Masson; 2001
94. Perrotta, R.; Bevelacqua, Y.; Malaguarnera, G.; Paladina, I.; Giordano, M.; Malaguarnera, M. Serum markers of cutaneous melanoma. Front. Biosci., 2010, 2, 1115-22.
95. Nitsche, N.; Hoffmann, K.; Iro, H. Ultrasound diagnosis of skin tumors. HNO, 1992, 40, 97-100.
96. Kapteijn, B.A.; Nieweg, O.E.; Liem, I.; Mooi, W.J.; Balm, A.J.; Muller, S.H. et al. Localising the sentinel node in cutaneous melanoma: Gamma probe detection versus blue dye. Ann. Surg. Oncol., 1997, 4, 156-160.
97. Morton, D.L.; Wen, D.R.; Wong, J.H.; Economou, J.S.; Cagle, L.A.; Storm, F.K. et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch. Surg., 1992, 127, 392-9.
98. Wong, J.H.; Cagle, L.A.; Morton, D.L. Lymphatic drainage of skin to a sentinel node in a feline model. Ann. Surg., 1991, 214, 637-641.
99. Wong, J.H.; Truelove, K.; Ko, P.; Coel, M.N. Localization and resection of an in transit sentinel lymph node by use of lymphoscintigraphy, intraoperative lymphatic mapping, and a hand-held gamma probe. Surgery, 1996, 1, 114-116.
100. Bartolomei, M.; Testori, A.; Chinol, M.; Gennari, R.; De Cicco, C.; Leonardi, L. et al. Sentinel node localization in cutaneous melanoma: Lymphoscintigraphy with colloids and antibody fragments versus blue dye mapping. Eur. J. Nucl. Med., 1998, 25, 1489-1494.
101. Godellas, C.V.; Berman, C.G.; Lyman, G.; Cruse, C.W.; Rapaport, D.; Heller, R. et al. The identification and mapping of melanoma regional nodal metastases: Minimally invasive surgery for the diagnosis of nodal metastases. Am. Surg., 1995, 61, 97-101.
102. Testori, A.; Soteldo, J.; Sances, D.; Mazzarol, G.; Trifirò, G.; Zonta, M.; Rastrelli, M.; Schenone, F.; Verrecchia, F. Cutaneous melanoma in the elderly. Melanoma Res., 2009 19,125-34
103. Owens, W.D.; Felts, J.A.; Spitznagel, E.L. ASA physical status classification: A study of consistency of ratings. Anesthesiology, 1978, 49, 239-243.
104. Chimenti, S.; Peris, K.; Di Cristofaro, S.; Fargnoli, M.C.; Torlone, G. Use of recombinant interferon alfa-2b in the treatment of basal cell carcinoma. Dermatology, 1995, 190, 214-7.
105. Fernández-Vozmediano, J.M.; Armario-Hita, J.C. Treatment of basal cell carcinoma of the nasal pyramid with intralesional interferon alfa-2b. J. Drugs Dermatol., 2010, 9, 381-4.
106. Kim, K., Yavel, R., Gross, V., Brody, N. Intralesional interferon a-2b in the treatment of basal cell carcinoma and squamous cell carcinoma. Revisited Dermatol. Surg., 2004, 30, 116-20.
107. Tucker, S., Polasek, J.; Perri, A.; Goldsmith, E. Long-term follow-up of basal cell carcinomas treated with perilesional interferon alfa 2b as monotherapy. J. Am. Acad. Dermatol., 2006, 54, 1033-38.
108. Stenquist, B.; Wennberg, A.; Gisslen, H.; Larko, O. Treatment of aggressive basal cell carcinoma with intralesional interferon: Evaluation of efficacy by Mohs surgery. J. Am. Acad. Dermatol., 1992, 27, 65-69
109. Edwards, L.; Berman, B.; Rapini, R.P.; Whiting, D.A.; Tyring, S.; Greenway, H.T.; Eyre, S.P.; Tanner, D.J.; Taylor, E.L.; Peets, E.; Smiles, K.A. Treatment of cutaneous squamous cell carcinomas by intralesional interferon alfa-2b therapy. Arch. Dermatol., 1992, 128, 1486-1489.
110. Julie Neville, A.; Welch, E.; Leffell, D.J. Management of nonmelanoma skin cancer in 2007. Nat. Clin. Pract. Oncol., 2007, 4, 462e9
111. Perrotta, R.E.; Giordano, M.; Malaguarnera, M. Non-melanoma skin cancers in elderly patients. Crit. Rev. Oncol. Hematol., 2011, 80(3), 474-80.
112. Chakrabarty, A.; Geisse, J.K. Medical therapies for non-melanoma skin cancer. Clin. Dermatol., 2004, 22, 183-8.
113. Neville, J.A.; Welch, E.; Leffell, D.J. Management of nonmelanoma skin cancer in 2007. Nat. Clin. Pract. Oncol., 2007, 4, 462-469.